Collaborative initiatives like A*STAR’s TISHUMAP project and companies such as Stratica Biosciences and 10x Genomics are pioneering spatial transcriptomics and AI integration to analyze thousands of clinical samples, particularly in cancer indications. These technologies enable precise cellular mapping in tumor microenvironments, potentially unveiling novel biomarkers and diagnostic tools. Parallel advances in single-cell sequencing and computational methods are accelerating drug target discovery and precision medicine development, refining understanding of tumor biology and patient response predictions.